INTRODUCTION
Haematopoietic SCT (HSCT) is increasingly used to treat patients suffering from malignant and non-malignant haematopoietic disorders. A frequent and potentially life threatening complication is GVHD whereby donor T cells attack host target organs causing substantial damage and apoptosis of cells giving rise to clinical symptoms of acute GVHD (aGVHD) followed by chronic GVHD (cGVHD). Severity of aGVHD is graded according to the number of organs involved and the severity of organ dysfunction 1 and occurs shortly after transplant whereas cGVHD either overlaps with aGVHD or is more delayed (after 100 days). The aGVHD process largely involves apoptosis and necrosis 2 with cGVHD having features resembling autoimmune diseases. 3 Allogeneic HSCT patients are given a conditioning regimen to maximise cytoreductive therapy and decrease graft rejection, however, this can cause the cytokine storm. 4 Cytokines, chemokines and their receptors have important roles in all phases of GVHD and their differential expression may be a determining factor of GVHD development and provide insight into its pathology. 5, 6 To date several studies have investigated predictive and prognostic biomarkers for GVHD including cytokines and chemokines. [7] [8] [9] [10] [11] [12] [13] [14] However, information regarding diagnostic, prognostic or predictive significance of these molecules in GVHD is limited. We selected candidate molecules from the literature which had previously been associated with either aGVHD or cGVHD [15] [16] [17] [18] for further validation as predictive, diagnostic or prognostic biomarkers. Donor-derived T cells are involved in initiation of aGVHD but also have a role in cGVHD, which has been classified as an independent disease. 1 The ability of patients to develop cGVHD after T-cell depletion suggests that other cell populations may have a role in its pathophysiology. 19 B cells have an important role in the immune response associated with cGVHD and are involved in GVHD biology. 3 cGVHD is associated with perturbed B-cell homeostasis and B-cell activating factor (BAFF) is a key regulator of normal B-cell homeostasis in both mice and humans. 20 Elevated levels of soluble BAFF have been reported in patients with autoimmune disease 21 and cGVHD. 22 Interleukin 33 (IL-33) is associated with inflammasome activation and danger signalling. 23 Recently, Toll-like receptors and Nucleotide Binding Oligomerization domain-like receptors have been investigated in GVHD. 24, 25 Both Toll-like receptors and Nucleotide Binding Oligomerization domain-like receptors have a role in sensing danger signals 26 and with caspase-1 are involved in the formation of the multi-protein complex, inflammasome, which upon recognition of pathogens leads to the release of IL-1β, IL-18 and IL-33. 27 Chemokines are small proteins that mediate migration of leukocyte trafficking in vivo. 28 The chemokines CXCL9, CXCL10 and CXCL11 are induced by interferon-γ, which is produced by Th1 cells. The receptor for these ligands, CXCR3, is predominantly expressed on the surface of Th1 cells and recent studies have demonstrated the involvement of the CXCR3 ligands in GVHD. 17 In this study, the role of BAFF, IL-33, CXCL10 and CXCL11 was investigated in aGVHD and cGVHD, pre and post allo-HSCT patient sera in a training and validation set as biomarker candidates for prediction or prognosis of acute or cGVHD. Results were further validated in the clinical GVHD biopsies and the human in vitro skin explant model, which can be used to induce a graft versus host reaction (GVHR) using donor and recipient HLA-matched skin and blood sample, as an in vitro model of GVHD. Table 1 . Sample/cohort size was based on previous studies in this research group and has been shown to be of adequate power. Patients at both centres received either myeloablative or reduced intensity conditioning regimens. Healthy blood donors (from Newcastle) were used as normal controls to determine baseline levels/expression of biomarkers and compared to samples from GVHD patients taken post HSCT. Diagnosis of aGVHD was according to clinical and histopathological criteria 32 and cGVHD by clinical assessment based on NIH criteria. 33 Patient samples
MATERIALS AND METHODS
In both centres peripheral blood and serum were collected from HSCT recipient patients before conditioning (7 days pre-transplant) and on days 0, 7, 14 and 28 and months 3, 6 and 12 following HSCT. 
Skin explant model
The skin explant assay was performed as previously described 29, 30 (for brief explanation, see Supplementary data).
Immunohistochemistry
Immunohistochemistry was performed on 3 μM sections from in vitro skin explants, skin or gut biopsies from GVHD patients. RNA extraction, cDNA production and real-time PCR RNA was extracted from healthy volunteer skin samples, clinical GVHD skin biopsies or skin explant assay samples, using the mirVana miRNA Isolation Kit (Ambion, Paisley, UK). cDNA was generated by random hexamer priming. Real-time PCR was performed using TaqMan assays for CXCL10 (Hs00171042_m1), CXCL11 (Hs00171138_m1) and BAFF (Hs00198106_m1) and the control gene GAPDH (Life Technologies, Paisley, UK). Reactions were set up in triplicate. A 7900 qRT-PCR system (Life Technologies) was used to run reactions and analysis (SDS 2.3 software, Applied Biosystems, Paisley, UK). The relative changes in RNA expression were calculated using the comparative ΔΔC t method. 34 
Statistical analysis
Non-parametric Mann-Whitney U test, two sample proportion test and chi-square tests were used to compare changes in cytokine/chemokine levels in skin explant assays, biopsies and patient sera. A comparison was made at each time point between patients with or without aGVHD or cGVHD. mRNA expression of biomarkers in positive (grade II4) and negative (less than grade II) skin explant assays were compared with medium alone controls. Skin explant GVHR grade was compared with clinical aGVHD outcome. The diagnostic performance of each biomarker was evaluated using Receiver Operating Characteristic (ROC) curve analysis (method explained in Supplementary data). Statistical analysis was carried out using Prism V5 (GraphPad, San Diego, CA, USA). A probability (P)o0.05 was considered to be statistically significant. P-value index *Po0.01, **Po0.001 and ***P o0.0001. Results are displayed in graphs as distribution of values measured with centre values as mean with s.e.m.
RESULTS
Cytokine/chemokine levels in HSCT patient sera Serum BAFF (sBAFF) levels were measured in recipient HSCT patients in a training cohort (Newcastle), validation cohort (Regensburg) and healthy individuals. Interestingly, sBAFF levels were significantly elevated pre-transplant in the aGVHD group compared with the no-aGVHD group in the training and validation cohort (Table 2, Figure 1a ). Following conditioning, sBAFF levels (21) 2 (5) Plasma cell neoplasm 2 (3)
Abbreviations: BAFF = B-cell activating factor; HSCT = haematopoietic SCT; IL-33 = interleukin 33; NCL = Newcastle Cohort; Rgn = Regensburg Cohort.
Identification of biomarkers associated with aGVHD and cGVHD SS Ahmed et al decreased on day 0 in the aGVHD group compared with pre-transplant levels in the same group in both cohorts (training, P = 0.01) (validation, P = 0.04) ( Figure 1a ). Post-transplant, sBAFF levels were significantly elevated on day 14 in the aGVHD group compared with the no-aGVHD group in the both cohorts (Table 2 , Figure 1a ). sBAFF levels in healthy individuals were significantly lower (P = 0.0003) compared with HSCT patients pre-transplant ( Figure 1a ). Development of aGVHD usually precedes cGVHD, 35 within the training cohort (n = 54) 45% of no-aGVHD patients developed cGVHD, compared with 75% of patients with aGVHD (P = 0.04). This confirms the risk of developing cGVHD is higher in the aGVHD group 36 and therefore may confirm BAFF as a predictive biomarker in cGVHD as recently reported. 16, 22 In cGVHD patients, sBAFF levels were significantly elevated at 12 months post transplant in the training cohort and 6 and 12 months post transplant in the validation cohort compared with the no-cGVHD group (Table 2, Figure 1b) . The onset of cGVHD at 6 months post transplant correlated with increased sBAFF levels (P = 0.02, data not shown) in the training cohort. Increased sBAFF levels at 12 months in both cohorts suggest that BAFF is indeed implicated in cGVHD and could serve as a diagnostic biomarker for cGVHD.
Treatment of patients with cGVHD often comprises steroid administration, which can reduce BAFF levels. 37, 38 Patients in the training cohort treated with steroids had lower sBAFF levels compared with patients without steroid treatment (data not shown). However, in the validation cohort, patients treated with steroids showed increased sBAFF levels at 6 months (P = 0.002, data not shown). In both cohorts, the majority of patients were administered with low-dose steroids (1-2 mg/kg), two patients from the training cohort and one patient from the validation cohort received high-dose steroids (42 mg/kg). Data analysis in relation to the different conditioning regimens showed no difference in sBAFF levels between patients receiving reduced intensity conditioning or myeloablative conditioning treatments (data not shown).
Next, we investigated levels of cytokine IL-33 in both cohorts. Soluble IL-33 levels were significantly higher in the aGVHD group compared with the no-aGVHD group on day 0 and day 28 post transplant in the training cohort and day 28 in the validation cohort (Table 2, Figure 1c ) indicating a potential role of IL-33 in predicting GVHD. sIL-33 levels in patients with cGVHD showed a significant increase at 3 months post transplant (*P = 0.03) in the cGVHD group, which could possibly be a continuation of aGVHD. However, in the validation cohort a significant decrease was observed in cGVHD patients compared with the no-cGVHD group (Table 2, Figure 1d ).
We then analysed CXCL10 and CXCL11 levels. CXCL10 levels were significantly increased pre-transplant in the aGVHD group in the training cohort only. Post-transplant, CXCL10 was significantly decreased in the training cohort aGVHD group on day 0 but then significantly increased on days 14 and 28 post transplant compared with patients with no-aGVHD. Correspondingly, a significant Abbreviations: aGVHD = acute GVHD; BAFF = B-cell activating factor; cGVHD = chronic GVHD; HSCT = haematopoietic SCT; IL-33 = interleukin 33. Only time points displaying a significant change in levels in the training cohort or validation cohort or in both are listed.
increase was also observed in the validation cohort on days 14 and 28 (Table 2, Figure 2a ) confirming an important role for CXCL10 in aGVHD. CXCL11 levels were also increased pre-transplant in aGVHD patients (*P = 0.03) in the training cohort only. Post transplant a significant increase was observed in both cohorts on days 14 and 28 in aGVHD patients (Table 2, Figure 2c ). In cGVHD patients, CXCL10 levels in the training cohort were significantly increased at 3, 6 and 12 months post transplant. This was confirmed at 6 and 12 months post transplant in the validation cohort ( Table 2 , Figure 2b ). CXCL11 levels in cGVHD patients were significantly increased at 6 and 12 months post transplant in the training cohort and significantly increased at 3, 6 and 12 months in the validation cohort ( Table 2 , Figure 2d ). The corresponding results from both cohorts confirm the suitability of CXCL10 and CXCL11 as diagnostic biomarkers for acute and cGVHD. The expression of proinflammatory chemokines in target tissues has been shown to be dependent on the conditioning regimen 39 and reported to be significantly increased after conditioning in comparison with normal controls. We also demonstrated increased levels of both CXCL10 and CXCL11 levels after either myeloablative or reduced intensity conditioning (see Supplementary data).
ROC curves
Training and validation cohort results were combined to determine diagnostic performance of each biomarker by ROC curve analysis pre-/post-transplant for aGVHD and cGVHD. The 3-month post-transplant time point was excluded as no significant changes were observed. An area under the curve (AUC) between 0.9 and 1.0 is considered excellent, between 0.8 and 0.9 good, 0.7-0.8 fair and 0.6-0.7 poor. Biomarkers that gave an AUC of 754 are listed in Figure 3 . For aGVHD, the AUC for IL-33 at day 0 was 0.78 and for CXCL10 at day 14 was 0.79. For cGVHD, the AUC was good for all biomarkers at 12 months post transplant (BAFF 0.85, IL-33 0.80, CXCL10 0.79 and CXCL11 0.75) at 6 months post transplant for BAFF (0.75) and pre-transplant for CXCL10 (0.78).
Confirmatory studies on skin explants and clinical biopsies
Cytokine/chemokine expression in the human in vitro skin explant assay. We investigated BAFF, IL-33, CXCL10 and CXCL11 protein expression in skin explant assays. BAFF expression was analysed in 23 allogeneic skin explants. The GVHR results were correlated with clinical aGVHD outcome for each patient and an 83% correlation (data not shown) was observed as previously reported. 31 Controls were skin incubated in medium alone or with autologous cells. BAFF expression in controls was similar to GVHR grade 0-I explant assays (54 and 56%, respectively), but significantly increased in grade II-III GVHR explants (mean positive cells 66%, P = 0.04) (Figure 4a ) demonstrating BAFF expression correlates with severity of GVHR. BAFF expression in normal healthy skin was significantly lower (P = 0.01) compared with grades II-III GVHR (data not shown). CXCL10 and CXCL11 expression was analysed in 20 skin explant assays. CXCL10 expression was significantly increased in the II-III GVHR group in comparison with the control group (medium only) (P = 0.007). No difference was observed between the control group and the grade 0-I GVHR group (Figure 4c ). CXCL11 expression was significantly increased in grade II-III GVHR skin explants compared with grade 0-I GVHR group (P = 0.01) (Figure 4d) . Moreover, only basal levels of CXCL10 and CXCL11 were observed in normal healthy skin (data not shown).
Cytokine/chemokine expression in clinical biopsies Clinical biopsies from HSCT patients were analysed for BAFF, IL-33 CXCL10 and CXCL11 protein expression by immunohistochemistry using clinical gastrointestinal (GI) tract biopsies (n = 17, 8 patients with clinical aGVHD and 9 patients with no-aGVHD). High BAFF expression was observed in 6/8 aGVHD biopsies (Figure 5a ), the no-aGVHD biopsies tested negative for BAFF staining (P = 0.001). The aGVHD GI biopsies all showed positive IL-33 staining (66.7% positive cells P = 0.01) (Figure 5b ) whereas 7/9 biopsies from noaGVHD patients were negative. To investigate further, mRNA expression was investigated in clinical skin biopsies taken from allo-HSCT patient's pre-/post transplant. BAFF mRNA expression in pre-transplant biopsies was used as a calibrator for expression in post-transplant biopsies and the histopathological aGVHD grades were used for analysis. BAFF mRNA expression was 23-fold higher in aGVHD (grade II-III) patients (n = 8) in comparison with no- (Figure 5d ) expression was more strongly distinctive in biopsies from patients with aGVHD. CXCL10 and CXCL11 mRNA expression in normal and clinical aGVHD skin showed low levels in normal skin, and significantly increased in aGVHD skin (P = 0.001 and P = 0.0003, respectively) (Figures 6a and  b) . Moreover, gene expression of CXCL10 and CXCL11 was also significantly increased in GVHR (grades II-III) positive skin explants (Figures 6c and d) in comparison with the medium control (P = 0.02, P = 0.02).
DISCUSSION
Elevated BAFF levels were previously reported in plasma of cGVHD patients. 16, 22 Our results show that sBAFF levels were already elevated pre-transplant in patients subsequently developing aGVHD indicating graft outcome may be influenced by transplant factors such as BAFF. Decreased sBAFF levels at day 0 suggested an effect of the conditioning treatment on BAFF producing cells. Following conditioning, a defect in cell-mediated immunity occurs resulting in disruption of B-cell homeostasis causing slow B-cell reconstitution and impaired functionality. 40 The sustained increase in BAFF levels observed in aGVHD patients following HSCT suggested delayed B-cell recovery, which may have contributed to loss of B-cell tolerance and development of cGVHD. 41 Elevated BAFF mRNA and protein expression confirmed its association with increased risk of developing aGVHD. Moreover, increased sBAFF levels in cGVHD patients provided strong support for BAFF involvement in cGVHD with pre-transplant levels predicting aGVHD outcome. Therefore, BAFF can be important for diagnosis or monitoring GVHD in response to acute and cGVHD therapy. Similarly, sIL-33 data suggest an important role for IL-33 in development of aGVHD as recently reported. 42 Chemokines have been implicated in allogeneic transplant rejection. 43, 44 The CXCR3 receptor and its ligands CXCL9/10/11 constitute an important pathway for effector cell recruitment post-transplant. 18, 45 Increased CXCL10 levels in sera and aGVHD skin biopsies 17, 46 have been reported but no involvement in cGVHD. The increase in CXCL10/CXCL11 levels in acute and expression was significantly increased (P = 0.007 and P = 0.01, respectively) in GVHR-positive skin explant assays compared with GVHR-negative skin explants. Representative immunohistochemistry images are given below each box plot showing expression in a GVHR-negative skin explant and a GVHR-positive skin explant for each cytokine/chemokine. All images were acquired using a light microscope (Leitz Wetzer) at × 50 magnification (1.32 OPL) and a digital camera (Canon, DS126071; Canon Utilities Browser EX software).
cGVHD patient sera suggests a potential biomarker role for both chemokines and suggests the perseverance of elevated CXCL10/ CXCL11 levels during aGVHD may lead to cGVHD development. Both CXCL10/CXCL11 were strongly influenced by conditioning treatment indicating conditioning induces early chemokine expression promoting T-cell migration into GVHD target organs and GVHD. Activation of chemokine expression using skin explant assays has recently been shown to induce T-cell migration and interferon-γ secretion exacerbating the GVHR. 47 Interestingly, the biomarkers investigated work collectively downstream of each another in inflammatory response initiation.
Inflammasome assembly at tissue damage sites results in caspase-1 release 48 and subsequent IL-33 activation 49 and binding to its receptor ST2 (suppressor of tumorigenicity-2). This elicits danger signals recognised by immune cells, which initiate an inflammatory response and express the CXCR3 receptor on the cell surface, resulting in CXCL10/CXCL11 binding and infiltration of effector T cells. ST2 itself has recently implicated as a biomarker for aGVHD. 50 In conclusion, the training and validation cohort results highlight association of the investigated biomarkers to GVHD. the skin explants strongly confirms association of each biomarker in predictive or diagnostic roles in aGVHD or cGVHD. Our results show a combination of different markers can be used to predict both acute and cGVHD; however, the use of a biomarker panel may be more effective to predict GVHD occurrence. Results are given relative to GAPDH and BAFF expression in pre-HSCT biopsies. BAFF expression was significantly higher in grades II-III acute GVHD patient biopsies in comparison with grades 0-I aGVHD. MannWhitney U test was used to determine significance.
